Wisconsin Ginseng for Decreasing Cancer Related Fatigue
In plain words A Phase 3 study of american ginseng in people 18 and older, run by Mayo Clinic. It plans to enroll about 160 people at 15 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Malignant Solid Neoplasm.
- Age ≥ 18 years
- Has received or is receiving treatment for a solid-organ malignancy (not hematologic)
- History of cancer-related fatigue as defined by an average score ≥ 4 over the past 30 days on the numeric analogue scale. Patients can answer questions orally rather than completing worksheet
- Baseline control of insomnia: Insomnia ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
American Ginseng; Placebo Administration; Questionnaire Administration
Registered summary
This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.
Where, as registered
15 US sites in 1 state.